PRESS RELEASE : MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications

DGAP-News: MagForce AG / Key word(s): Miscellaneous 
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the 
Deadliest Oncological Indications 
2021-06-07 / 08:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the 
Deadliest Oncological Indications 
Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a 
leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System 
for the treatment of brain tumors, supports World Brain Tumor Day on June 8^th, 2021 and informs about various virtual 
patient events to raise awareness for this devastating disease. 
"Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly 
fatal disease. Despite major advances in treatment modalities, malignant tumors of the brain remain largely incurable 
and an unresolved therapeutic problem. At MagForce it is our mission to provide patients with a further treatment 
option and make our innovative approach based on nanotechnology available all over the world," said Ben Lipps, CEO of 
MagForce AG and MagForce USA, Inc. "Keeping in line with tradition, I am happy that MagForce once again has the 
opportunity to support affiliated brain tumor centers in their numerous activities for brain tumor patients and their 
caregivers on occasion of the World Brain Tumor Day." 
Zwickau, Germany - Paracelsus Clinic Zwickau Hosts Patient Hotline "Meet a Professor" 
In 2019, the Paracelsus Clinic Zwickau and MagForce announced their cooperation on the occasion of 20^th anniversary of 
the World Brain Tumor Day, one of four clinics in Europe to offer MagForce's NanoTherm Therapy System for the treatment 
of brain tumors. Headed by Prof. Dr. med. habil. Jan-Peter Warnke, the department of neurosurgery cares for 
approximately 2,200 patients annually and performs an average of 1,500 surgeries per year, of which approximately 300 
are primary gliomas. 
This year, the Paracelsus Clinic Zwickau will host an open hotline "Meet a Professor" where patients will be able to 
put forth any questions they may have regarding brain tumors and multiple treatment options. Prof. Dr. med. Habil. 
Warnke and Christian Schürer, Assistant Physician and contact for the NanoTherm Therapy System at the Paracelsus Clinic 
Zwickau, will be available from 9am to 3pm to answer questions on the subject of glioblastomas and the NanoTherm 
Therapy as an alternative treatment option. 
When: Tuesday, June 8th, 2021, 9am-3pm CEST 
Phone: [phone] 
Lublin, Poland - Alivia Cancer Foundation, SPSK4 Hospital and MagForce Invite you to join their Infoline on the 
Treatment of Brain Tumors Using the NanoTherm Therapy System 
According to estimates, every fourth inhabitant of Poland is diagnosed with cancer during their lifetime, and every 
fifth will die from it. Although recent years have brought about rapid progress in the knowledge of pathomechanisms 
underlying each cancer, and cancer itself, contributing to many new drugs and therapies being launched onto the market, 
access to effective treatment options in Poland remain limited. As a result, the average Pole has a lower chance to 
survive 5 years with cancer compared to citizens of other European countries. 
The Independent Public Clinical Hospital No. 4 (SPSK4) in Lublin, one of the leading brain treatment centers in Poland, 
is the first hospital outside of Germany to offer MagForce's NanoTherm Therapy System as an additional treatment option 
allowing Polish patients to receive treatment in their home country and provide faster access to the therapy for 
patients from surrounding countries. 
On occasion of the 2021 World Brain Tumor Day, the SPSK4 will host a free Infoline, supported by MagForce and Alivia 
Cancer Foundation. Prof. Tomasz Trojanowski, Polish National Consultant for Neurosurgery and a member of the Scientific 
Advisory Board of the Minister of Health of Poland, Prof. Radoslaw Rola, Head and Chairman of the Neurosurgery and 
Paediatric Neurosurgery Departments, and Dr Jacek Wozniak, Specialist of the Center for Innovative Therapies, will be 
available for a free consultation and answer all patient question regarding the NanoTherm Therapy System at SPSK4. 
When: Tuesday, June 8^th at 9am-3pm (Dr. Jacek Wozniak) and 3pm-4pm CEST (Prof. Tomasz Trojanowski and Prof. Radoslaw 
Rola) 
Phone: [phone] 
DGNC 2021, Virtual - MagForce is Main Sponsor of the Leading Conference in the Field of Neurosurgery 
Taking place around the World Brain Tumor Day from June 6-9, the 72nd Annual Meeting of the German Society of 
Neurosurgery (DGNC) held jointly with the Polish Society of Neurosurgeons will provide a virtual platform to present 
scientific findings, discuss new innovative treatments and exchange information about the most recent research results 
and future visions. 
As main-sponsor, MagForce is excited to support this important event in the field of neurosurgery and represented with 
a virtual booth, where MagForce representatives are available for questions regarding its NanoTherm Therapy System. 
For more information on the 2021 DGNC Meeting programme, please click here. 
About World Brain Tumor Day 
Declared by the Deutsche Hirntumorhilfe (German Brain Tumour Association) in 2000 as an international commemoration 
day, the World Brain Tumor Day is celebrated every year on June 8^th to raise awareness about brain tumours and inspire 
hope for patients living with this disease. According to current information from the Deutsche Hirntumorhilfe^[i], each 
year, more than 8,000 people are diagnosed with a primary brain tumor in Germany alone. Glioblastoma is the most common 
and aggressive form of brain tumors in adults with an incidence, i.e. the number of new cases per year, of about three 
patients per 100,000 people. Worldwide, over 700 new cases are recorded on a daily basis. Additionally, many other 
types of cancer cause metastases in the brain, which are known as secondary brain tumors. Despite major advances in 
treatment modalities, malignant tumors of the brain remain largely incurable and an unresolved therapeutic problem. 
The NanoThermTherapy System for the Treatment of Brain Tumors 
MagForce's NanoTherm Therapy System provides a novel, nanotechnology-based approach for the treatment of solid tumors 
by introducing magnetic nanoparticles either directly into the tumor or into the resection cavity wall. At the 
discretion of the attending neurosurgeon, the NanoTherm liquid containing the magnetic nanoparticles can be instilled 
in the course of the tumor resection, keeping interventions to a minimum. The particles are subsequently heated by an 
alternating magnetic field that allows targeted treatment by irreparably destroying, or weakening, cancer cells making 
them more sensitive to concomitant radiotherapy or chemotherapy. These sessions generally take place over a three-week 
period, either in an in-patient or out-patient setting depending on the patients condition, and are nearly completely 
free of pain and discomfort. The limited time span required for the treatment makes the therapy highly predictable and 
allows the patient to return to everyday life and regain significant quality of life as far and as soon as possible. 
Since the particles remain at the site of instillation due to their special coating, the surrounding healthy tissue is 
spared and the integration into multimodal therapy concepts are made possible. 
 
MagForce AG was granted the European CE certificate ("European Certification") and thus the official approval of the 
NanoTherm Therapy System for the treatment of brain tumors in Germany and all member states of the European Union. 
About MagForce AG and MagForce USA, Inc. 
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its 
subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The 
Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral 
generation of heat via activation of superparamagnetic nanoparticles. 
NanoTherm^(R), NanoPlan^(R), and NanoActivator^(R) are components of the therapy and have received EU-wide regulatory 
approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are 
trademarks of MagForce AG in selected countries. 
For more information, please visit: www.magforce.com 
Get to know our Technology: video (You Tube) 
Stay informed and subscribe to our mailing list 
Contact: 
Barbara von Frankenberg 
VP Communications & Investor Relations 
T [phone] 
M [e-mail] 
 
Disclaimer 
This release may contain forward-looking statements and information which may be identified by formulations using terms 
such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such 
forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a 
variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these 
forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct 
them in case of developments, which differ from those, anticipated. 
^[i] Deutsche Hirntumorhilfe, https://www.hirntumorhilfe.de/projekte/welthirntumortag1/ 
 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-07 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 

(MORE TO FOLLOW) Dow Jones Newswires

June 07, 2021 02:31 ET (06:31 GMT)